Duel Therapeutics Enters Licensing Deal with Bristol-Myers Squibb

Duel Therapeutics, a BioMotiv spinoff, has entered an oncology strategic collaboration with Bristol-Myers Squibb. Duel Therapeutics will receive an undisclosed upfront fee and is eligible to additional payments if it hits development milestones up to $255 million.

Read More  >